Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,007,065

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences

Today's Research Daily features new research reports on 16 major stocks, including NIKE (NKE), Cisco Systems (CSCO) and Gilead Sciences (GILD)

    Sanghamitra Saha headshot

    5 ETF Picks for October

    A few ETF choices for the month of October.

      Arpita Dutt headshot

      Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation

      Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.

        Ryan McQueeney headshot

        Here's Why Bluebird Bio (BLUE) Stock Is Falling Today

        Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.

          Merck Drops Two HCV Combination Programs Amid Competition

          Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.

            How Will Trump's Proposed Tax Reform Impact Drug Companies?

            Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.

              Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China

              Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.

                Intercept (ICPT) Provides Safety Guidelines For Ocaliva

                Intercept Pharmaceuticals, Inc. (ICPT) provided a statement on the recent safety and dosing issues for lead drug Ocaliva and reinforced that the recommended dosing is safe.

                  Kite Pharma Triples So Far in 2017: What's Driving the Rally?

                  Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues

                    Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.

                      Gilead's (GILD) Epclusa Receives Label Expansion in Canada

                      Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

                        4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

                        Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

                          Should Value Investors Consider Gilead Sciences (GILD) Stock?

                          Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.

                            4 Biotech Stocks That Show Promise on Sustainable Growth

                            Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.

                              Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock

                              Gilead Sciences (GILD) needs Investors to pay close attention to the stock based on moves in the options market lately.

                                3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

                                The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

                                  The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger

                                  The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger

                                    Arpita Dutt headshot

                                    5 Top-Ranked Biotech Stocks to Buy Right Now

                                    If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

                                      Top Ranked Income Stocks to Buy for September 8th

                                      Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 8th:

                                        Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus

                                        With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.

                                          Mallinckrodt Down as District Court Invalidates Inomax Patents

                                          Shares of Mallinckrodt plc (MNK) were down 12.3% after a U.S. District Court invalidated 11 patents covering its second-largest product Inomax.

                                            Buy These 5 Large Caps on Extraordinary ROI Potential

                                            Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.

                                              4 Biotech Stocks to Improve Your Portfolio's Health

                                              The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016.

                                                The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences

                                                The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences

                                                  Arpita Dutt headshot

                                                  Biotech Stocks Back in Favor: Will the Rally Continue?

                                                  Interest in the biotech sector has picked up with the Gilead (GILD)-Kite acquisition announcement. Will the rally continue?